Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;84(9):956-62.
doi: 10.1136/jnnp-2012-304644. Epub 2013 Mar 30.

TDP-43 Frontotemporal Lobar Degeneration and Autoimmune Disease

Affiliations
Free PMC article

TDP-43 Frontotemporal Lobar Degeneration and Autoimmune Disease

Zachary A Miller et al. J Neurol Neurosurg Psychiatry. .
Free PMC article

Abstract

Background: The aetiology and pathogenesis of non-genetic forms of frontotemporal dementia (FTD) is unknown and even with the genetic forms of FTD, pathogenesis remains elusive. Given the association between systemic inflammation and other neurodegenerative processes, links between autoimmunity and FTD need to be explored.

Objective: To describe the prevalence of systemic autoimmune disease in semantic variant primary progressive aphasia (svPPA), a clinical cohort, and in progranulin (PGRN) mutation carriers compared with neurologically healthy normal controls (NC) and Alzheimer's disease (AD) as dementia controls.

Design: Case control.

Setting: Academic medical centres.

Participants: 129 svPPA, 39 PGRN, 186 NC and 158 AD patients underwent chart review for autoimmune conditions. A large subset of svPPA, PGRN and NC cohorts underwent serum analysis for tumour necrosis factor α (TNF-α) levels.

Outcome measures: χ(2) Comparison of autoimmune prevalence and follow-up logistic regression.

Results: There was a significantly increased risk of autoimmune disorders clustered around inflammatory arthritides, cutaneous disorders and gastrointestinal conditions in the svPPA and PGRN cohorts. Elevated TNF-α levels were observed in svPPA and PGRN compared with NC.

Conclusions: svPPA and PGRN are associated with increased prevalence of specific and related autoimmune diseases compared with NC and AD. These findings suggest a unique pattern of systemic inflammation in svPPA and PGRN and open new research avenues for understanding and treating disorders associated with underlying transactive response DNA-binding protein 43 aggregation.

Keywords: DEMENTIA; EPIDEMIOLOGY; IMMUNOLOGY; RHEUMATOLOGY.

Figures

Figure 1
Figure 1
Prevalence of Autoimmune Disease among Diagnostic Groups. Abbreviations: AD = Alzheimer’s disease; NC = normal controls; PGRN = progranulin; svPPA = semantic variant primary progressive aphasia. Retrospective chart review of autoimmune conditions in AD, NC, PGRN, and svPPA subjects. Other Autoimmune refers to all other autoimmune conditions on the collection instrument that were not thyroid disease. When an individual had a thyroid disorder and another autoimmune disease they were assigned to the Other Autoimmune category, so as to avoid being counted twice. Thyroid Only refers to those who had only thyroid spectrum disorders affecting subjects. Nothing Mentioned refers to individuals where there was no mention of any condition found within the screening collection instrument. * ** Two patients in the collection overlapped between the PGRN and svPPA cohort (one had type 1 diabetes and thyroid disease and the other had no mentioned autoimmune disorder).
Figure 2
Figure 2
TNF-α Levels in NC, PGRN, and svPPA. Abbreviations: NC = normal control; PGRN = progranulin; svPPA = semantic variant primary progressive aphasia; TNF-α = tumor necrosis factor alpha. Samples from NC (37), PGRN (24), and svPPA (26) were analyzed for plasma TNF-α levels. * ** Statistical differences in TNF-α levels were found between NC and PGRN as well as NC and svPPA (p = 0.0075 and p = 0.012, respectively; t test)..
Figure 3
Figure 3
Model of Relative Increased TNF-α Signaling in TDP-43 Disease, Via PGRN Depletion or TNF-α Elevation. Abbreviations: PGRN = progranulin; TDP-43 = transactive response DNA-binding protein 43; TNF-α = tumor necrosis factor alpha. Proposed unifying schema for TDP-43 disease pathology mediated through the effects of TNF-α signaling. Above, (A) represents primary PGRN and secondary TNF-α mediated mechanisms while (B) represents a primary TNF-α mediated mechanism of TDP-43 disease. These two mechanisms likely interact with each other.

Comment in

Similar articles

See all similar articles

Cited by 51 articles

  • Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O. Leuzy A, et al. JAMA Neurol. 2020 May 11:e200989. doi: 10.1001/jamaneurol.2020.0989. Online ahead of print. JAMA Neurol. 2020. PMID: 32391858 Free PMC article.
  • Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum.
    Bevan-Jones WR, Cope TE, Jones PS, Kaalund SS, Passamonti L, Allinson K, Green O, Hong YT, Fryer TD, Arnold R, Coles JP, Aigbirhio FI, Larner AJ, Patterson K, O'Brien JT, Rowe JB. Bevan-Jones WR, et al. Brain. 2020 Mar 1;143(3):1010-1026. doi: 10.1093/brain/awaa033. Brain. 2020. PMID: 32179883 Free PMC article.
  • Uncovering pathophysiological changes in frontotemporal dementia using serum lipids.
    Phan K, He Y, Pickford R, Bhatia S, Katzeff JS, Hodges JR, Piguet O, Halliday GM, Kim WS. Phan K, et al. Sci Rep. 2020 Feb 27;10(1):3640. doi: 10.1038/s41598-020-60457-w. Sci Rep. 2020. PMID: 32107421 Free PMC article.
  • Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.
    Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S, Bocchetta M, Boeve BF, Knopman DS, Graff-Radford NR, Forsberg LK, Rademakers R, Wszolek ZK, van Swieten JC, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Snowden JS, Saxon J, Jones M, Pickering-Brown S, Le Ber I, Camuzat A, Brice A, Caroppo P, Ghidoni R, Pievani M, Benussi L, Binetti G, Dickerson BC, Lucente D, Krivensky S, Graff C, Öijerstedt L, Fallström M, Thonberg H, Ghoshal N, Morris JC, Borroni B, Benussi A, Padovani A, Galimberti D, Scarpini E, Fumagalli GG, Mackenzie IR, Hsiung GR, Sengdy P, Boxer AL, Rosen H, Taylor JB, Synofzik M, Wilke C, Sulzer P, Hodges JR, Halliday G, Kwok J, Sanchez-Valle R, Lladó A, Borrego-Ecija S, Santana I, Almeida MR, Tábuas-Pereira M, Moreno F, Barandiaran M, Indakoetxea B, Levin J, Danek A, Rowe JB, Cope TE, Otto M, Anderl-Straub S, de Mendonça A, Maruta C, Masellis M, Black SE, Couratier P, Lautrette G, Huey ED, Sorbi S, Nacmias B, Laforce R Jr, Tremblay ML, Vandenberghe R, Damme PV, Rogalski EJ, Weintraub S, Gerhard A, Onyike CU, Ducharme S, Papageorgiou SG, Ng ASL, Brodtmann A, Finger E, Guerreiro R, Bras J, Rohrer JD; FTD Prevention Initiative. Moore KM, et al. Lancet Neurol. 2020 Feb;19(2):145-156. doi: 10.1016/S1474-4422(19)30394-1. Epub 2019 Dec 3. Lancet Neurol. 2020. PMID: 31810826
  • Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency.
    Ljubenkov PA, Miller Z, Mumford P, Zhang J, Allen IE, Mitic L, Staffaroni A, Heuer H, Rojas JC, Cobigo Y, Karydas A, Pearlman R, Miller B, Kramer JH, McGrath MS, Rosen HJ, Boxer AL. Ljubenkov PA, et al. Front Neurol. 2019 Sep 18;10:1004. doi: 10.3389/fneur.2019.01004. eCollection 2019. Front Neurol. 2019. PMID: 31620075 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback